• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PYXS

    Pyxis Oncology Inc.

    Subscribe to $PYXS
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: pyxisoncology.com

    Peers

    $PXS

    Recent Analyst Ratings for Pyxis Oncology Inc.

    DatePrice TargetRatingAnalyst
    11/21/2024Outperform → Mkt Perform
    William Blair
    11/8/2024$13.00Overweight
    Stephens
    8/8/2024$10.00Buy
    Stifel
    5/7/2024$10.00Buy
    Jefferies
    2/9/2024$8.00Buy
    BTIG Research
    1/23/2024$12.00Outperform
    Leerink Partners
    9/5/2023$7.00Outperform
    RBC Capital Mkts
    11/2/2021$16.00Neutral
    B of A Securities
    11/2/2021$25.00Buy
    Jefferies
    11/2/2021$19.00Outperform
    Credit Suisse
    See more ratings

    Pyxis Oncology Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President ,CEO & CMO Sullivan Lara

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:06:50 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Metzger Michael A

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:05:43 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SVP, Chief Accounting Officer Wadhane Jitendra

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:04:17 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Humphrey Rachel

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:03:25 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lewis-Hall Freda C

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:02:32 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cline Darren S

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:01:38 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Dupont Jakob

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:00:15 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Palani Santhosh

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 8:58:35 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Civik Thomas

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 8:57:37 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CFO & COO Connealy Pamela Ann

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 8:56:28 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care